A Canadian company's cheap generic version of the blood thinner Plavix has been blocked from the U.S. market until at least 2011. U.S. District Judge Sidney H. Stein said Tuesday that Apotex Inc. had failed to prove during a three-week trial in New York City earlier this year that the...
> The FDA has told Sanofi-Synthelabo to stop using a visual sales aid for its antiplatelet drug Plavix clopidogrel bisulfate because it overstated the efficacy of the drug, according to a just-released May 8 notice-of-violation letter. The aid is misleading, wrote Division of Drug Marketing, Advertising, and Communications reviewer Andrew...
WESTON, Fla. -- Apotex Inc. and Apotex Corp. announced today that they have reached an agreement with Sanofi-aventis and Bristol-Myers Squibb, subject to certain conditions, to settle the patent infringement lawsuit pending between the parties in the U.S. District Court for the Southern District of New York. The lawsuit relates...
After a false start, Bristol-Myers Squibb Co. is ready to launch the first direct-to-consumer advertising for Plavix, its prescription heart attack and stroke prevention drug. After a false start, Bristol-Myers Squibb Co. is ready to launch the first direct-to-consumer advertising for Plavix, its prescription...
[New York] Bristol-Myers Squibb Co. put the advertising assignment for prescription blood-thinning medication Plavix into review after parting ways with WPP Group's Ogilvy & Mather, New York, executives close to the situation said. An Ogilvy spok [New York] Bristol-Myers Squibb Co. put the advertising assignment ...
Bristol-Myers Squibb and Sanofi-Synthelabo, co-marketers of Plavix, awarded the $70 million account to Publicis Groupe's Saatchi & Saatchi Healthcare, a Bristol-Myers spokesman confirmed. The prescription blood-thinning medication is the market l Bristol-Myers Squibb and Sanofi-Synthelabo, co-marketers of Plavix, awarded the $70 million account to Publicis...
Question-and-Answer SessionThank you, sir. [Operator Instructions]. I'll take our first question from Tim Anderson at Stanford Bernstein. Tim Anderson - Stanford Bernstein Thank you. Few question. Just to be clear, on Mead Johnson when you say you plan on keeping the 80% to 90% of the business for the...
Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover and Aspirin, According to a New Report from Decision Resources
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c56821) has announced the addition of Chile Pharmaceuticals & Healthcare Report Q4 2006 to their offering
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c40566) has announced the addition of the Espicom Business Intelligence Ltd report: Bristol-Myers Squibb Pharmaceutical Company Intelligence Report to their offering.
Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Tom Gallucci with Merrill Lynch Tom Gallucci-Merrill Lynch Good morning, thanks for all the color. Just one clarification and then a question, Dave you had mentioned sort of the relative profitability, I...
CHICAGO -- Fitch Ratings places Bristol-Myers Squibb's (Bristol-Myers) 'A+' issuer default, senior unsecured debt, and bank loan ratings, and 'F1' commercial paper rating on Rating Watch Negative. The ratings apply to approximately $8.43 billion of outstanding debt. The rating action follows Apotex Inc.'s Apotex announcement of its launch of a...
Mike Huckman submits: Last week I blogged about Eli Lilly's LLY "Coming Soon" banner ad I spotted in the online edition of The New England Journal of Medicine. It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month....
Question-and-Answer SessionOperator Operator Instructions. Your first question comes from Tom Gallucci with Merrill Lynch. Tom Gallucci - Merrill Lynch Good morning. Thanks for all the color. I guess Rich, just a follow up on what you were just discussing there in terms of guidance. As you went through the...
By Ben Hirschler LONDON (Reuters UK) - Chris Viehbacher, GlaxoSmithKline's GSK head of North American pharmaceuticals, is to take a top job at French drugmaker Sanofi-Aventis SASY, according to a person familiar with the situation. His exact role was not immediately clear but he is thought...
With AT&T Tech Support 360, you'll have certified, U.S. based technicians on call 24/7 to help keep your computers, connections, software and peripherals up to speed for just 82¢ a day.
